Amneal Pharmaceuticals, Inc. (AMRX)
NASDAQ: AMRX · Real-Time Price · USD
13.17
+0.22 (1.70%)
At close: May 29, 2026, 4:00 PM EDT
13.01
-0.16 (-1.21%)
After-hours: May 29, 2026, 7:41 PM EDT
Amneal Pharmaceuticals Stock Forecast
Stock Price Forecast
According to 5 analysts polled by S&P Global, Amneal Pharmaceuticals stock has a consensus rating of "Strong Buy" and an average price target of $17.2. The average 1-year stock price forecast is 30.60% higher than the current stock price, while the lowest is $16 (+21.49%) and the highest is $19 (+44.27%).
Price Target: $17.2 (+30.60%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Amneal Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 3 | 3 |
| Buy | 3 | 3 | 3 | 3 | 2 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 5 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Goldman Sachs | Goldman Sachs | Buy Reiterates $17 | Buy | Reiterates | $17 | +29.08% | May 28, 2026 |
| Piper Sandler | Piper Sandler | Buy Reiterates $17 | Buy | Reiterates | $17 | +29.08% | May 26, 2026 |
| Barclays | Barclays | Buy Maintains $15 → $16 | Buy | Maintains | $15 → $16 | +21.49% | May 20, 2026 |
| Truist Financial | Truist Financial | Buy Maintains n/a | Buy | Maintains | n/a | n/a | Apr 23, 2026 |
| UBS | UBS | Buy Initiates $19 | Buy | Initiates | $19 | +44.27% | Apr 17, 2026 |
Financial Forecast
Revenue This Year
3.17B
from 3.02B
Increased by 4.88%
Revenue Next Year
3.40B
from 3.17B
Increased by 7.36%
EPS This Year
1.01
from 0.22
Increased by 358.15%
EPS Next Year
1.18
from 1.01
Increased by 16.90%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 3.3B | 3.5B | |||
| Avg | 3.2B | 3.4B | |||
| Low | 3.0B | 3.2B |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 8.8% | 12.0% | |||
| Avg | 4.9% | 7.4% | |||
| Low | 0.1% | 0.9% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 1.06 | 1.28 | |
| Avg | 1.01 | 1.18 | |
| Low | 0.92 | 1.02 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 382.0% | 27.1% | |
| Avg | 358.2% | 16.9% | |
| Low | 318.3% | 1.2% |
Sources: Price targets and consensus ratings provided by S&P Global Market Intelligence. Historical ratings and analyst data provided by TipRanks. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data sources.